Healthcare -
Drug Manufacturers - General - NYSE - GB
$ 33.43
-0.0299 %
$ 68.2 B
Market Cap
22.59
P/E
1. INTRINSIC VALUE
Balance Sheet
GSK plc
| Current Assets | 18.6 B |
| Cash & Short-Term Investments | 4.99 B |
| Receivables | 5.9 B |
| Other Current Assets | 7.75 B |
| Non-Current Assets | 40.4 B |
| Long-Term Investments | 2.14 B |
| PP&E | 9.96 B |
| Other Non-Current Assets | 28.3 B |
| Current Liabilities | 21.1 B |
| Accounts Payable | 3.72 B |
| Short-Term Debt | 2.81 B |
| Other Current Liabilities | 14.5 B |
| Non-Current Liabilities | 25.1 B |
| Long-Term Debt | 15.2 B |
| Other Non-Current Liabilities | 9.94 B |
EFFICIENCY
Earnings Waterfall
GSK plc
| Revenue | 30.3 B |
| Cost Of Revenue | 8.56 B |
| Gross Profit | 21.8 B |
| Operating Expenses | 15 B |
| Operating Income | 6.74 B |
| Other Expenses | 1.82 B |
| Net Income | 4.93 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GSK plc
| Net Income | 4.93 B |
| Depreciation & Amortization | 2.29 B |
| Capital Expenditures | -2.34 B |
| Stock-Based Compensation | 307 M |
| Change in Working Capital | -841 M |
| Others | 1.19 B |
| Free Cash Flow | 4.42 B |
Wall Street Analysts Price Targets
GSK plc
Wall Street analysts predict an average 1-year price target for GSK of $58 , with forecasts ranging from
a
low of
$36 to a high of $85 .
GSK Lowest Price Target
Wall Street Target
36 USD
7.69%
GSK Average Price Target
Wall Street Target
58 USD
73.50%
GSK Highest Price Target
Wall Street Target
85 USD
154.26%
4. DIVIDEND
ANALYSIS
0.99%
DIVIDEND YIELD
0.389 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
GSK plc
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tuesday.
reuters.com
- 1 week ago
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
zacks.com
- 1 week ago
GSK's experimental cancer drug wins receives support from US regulator
GSK PLC (LSE:GSK, NYSE:GSK) has received a major boost for its experimental drug GSK5764227 (GSK'227), which targets a rare and aggressive bone cancer called osteosarcoma. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the treatment, which is being tested for patients whose cancer has returned after at least two prior treatments.
proactiveinvestors.co.uk
- 1 week ago
GSK's Nucala approved in China for treating nasal polyps
GSK PLC's (LSE:GSK, NYSE:GSK) Nucala (mepolizumab) has been approved in China to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP) when other therapies, like steroids or surgery, have not worked. This makes Nucala the first anti-interleukin-5 treatment available for this condition in China, where an estimated 30 million people live with CRSwNP.
proactiveinvestors.co.uk
- 2 weeks ago
GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or 'endpoint'. The study showed that the addition of Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, significantly improved progression-free survival (PFS) in first-line advanced ovarian cancer.
proactiveinvestors.co.uk
- 1 month ago
GSK's cancer drugs meet progression-free survival goal in late-stage trial
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial.
reuters.com
- 1 month ago
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
zacks.com
- 1 month ago
GSK passes three significant milestones with new cancer drug given a double boost
GSK PLC (LSE:GSK, NYSE:GSK) has announced significant progress in its oncology pipeline, achieving three milestones. The European Medicines Agency (EMA) has issued a positive opinion recommending the expanded approval of Jemperli (dostarlimab) with chemotherapy for first-line treatment of advanced or recurrent endometrial cancer.
proactiveinvestors.co.uk
- 1 month ago
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
zacks.com
- 1 month ago
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
FOR IMMEDIATE RELEASE Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
globenewswire.com
- 1 month ago
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying computation and experimentation to drug discovery, today announced two multi-program strategic collaborations with GSK. The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis.
globenewswire.com
- 1 month ago
GSK says blood cancer drug shows dramatic survival gains in key trial
GSK PLC (LSE:GSK, NYSE:GSK) shares in New York rose Monday afternoon after it announced that its blood cancer drug Blenrep (belantamab mafodotin) significantly extended survival in a pivotal trial. The drug, combined with two other therapies, reduced the risk of death by 42% compared to a rival treatment from Johnson & Johnson (NYSE:JNJ), according to results presented at the American Society of Hematology's annual meeting.
proactiveinvestors.com
- 1 month ago
8. Profile
Summary
GSK plc GSK
COUNTRY
GB
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 68.2 B
Dividend Yield
0.99%
Description
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Contact
980 Great West Road, Brentford, TW8 9GS
https://www.gsk.com
IPO
Date
March 28, 1980
Employees
70212
Officers
Ms. Emma Natasha Walmsley
Chief Executive Officer & Director
Ms. Sally Jackson
Senior Vice President of Global Communications & Chief Executive Officer Office
Ms. Diana Conrad
Chief People Officer
Mr. James Ford
Senior Vice President & Group General Counsel of Legal & Compliance
Ms. Julie Belita Brown A.C.A.
Chief Financial Officer & Executive Director
Mr. Philip C. Thomson
President of Global Affairs
Mr. David Simon Redfern BSc (Hons), CA
President of Corporate Development
Ms. Shobie Ramakrishnan
Chief Digital & Technology Officer
Mr. Tony Wood
Chief Scientific Officer and Head of R&D
Mr. Nick Stone
SVice President & Head of Investor Relations